ESR1 and breast carcinoma: The authors examined 112 ER-positive primary breast carcinomas from patients with advanced disease and clearly defined therapy response types (i.e., 52 patients with objective response vs. 60 patients with progressive disease) from start of first-line treatment with tamoxifen.